Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.06.19
Views: 567
Rating:

Prof Xavier Leleu - Centre Hospitalier Universitaire de Lille, Lille, France

Prof Xavier Leleu talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the use of weekly carfilzomib as a maintenance therapy in elderly patients with newly diagnosed multiple myeloma.

He describes this study, in which the researchers aimed to demonstrate the use of carfilzomib in these patients, as an alternative standard of care drug.

Prof Leleu also discusses the results from this phase I study, where patients underwent 13 cycles of maintenance. Only 4 patients from the study group were unable to complete this, however, overall this treatment was proven feasible and effective in elderly patients upfront.

He notes the potential incorporation of carfilzomib in the lenalidomide plus dexamethasone regimen for these patients in the future.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation